- Home
- CMA vs HALO Comparison
CMA vs HALO Comparison
Compare CMA & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMA
- HALO
- Stock Information
- Founded
- CMA 1849
- HALO 1998
- Country
- CMA United States
- HALO United States
- Employees
- CMA N/A
- HALO N/A
- Industry
- CMA Major Banks
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMA Finance
- HALO Health Care
- Exchange
- CMA Nasdaq
- HALO Nasdaq
- Market Cap
- CMA 7.1B
- HALO 7.4B
- IPO Year
- CMA N/A
- HALO N/A
- Fundamental
- Price
- CMA $58.81
- HALO $52.02
- Analyst Decision
- CMA Hold
- HALO Buy
- Analyst Count
- CMA 20
- HALO 9
- Target Price
- CMA $62.95
- HALO $63.56
- AVG Volume (30 Days)
- CMA 1.5M
- HALO 3.1M
- Earning Date
- CMA 04-21-2025
- HALO 05-06-2025
- Dividend Yield
- CMA 4.83%
- HALO N/A
- EPS Growth
- CMA 4.95
- HALO 55.40
- EPS
- CMA 5.29
- HALO 3.76
- Revenue
- CMA $3,234,000,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- CMA $7.20
- HALO $24.79
- Revenue Next Year
- CMA $3.01
- HALO $22.65
- P/E Ratio
- CMA $11.12
- HALO $13.83
- Revenue Growth
- CMA N/A
- HALO 25.64
- 52 Week Low
- CMA $45.32
- HALO $41.28
- 52 Week High
- CMA $73.45
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- CMA 62.43
- HALO 39.78
- Support Level
- CMA $54.42
- HALO $47.50
- Resistance Level
- CMA $59.36
- HALO $69.94
- Average True Range (ATR)
- CMA 1.16
- HALO 3.52
- MACD
- CMA 0.62
- HALO -1.49
- Stochastic Oscillator
- CMA 91.83
- HALO 19.64
About CMA Comerica Incorporated
With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.